Heart:看国外急性冠脉综合征的管理特点和结果!

2018-02-20 MedSci MedSci原创

斯里兰卡的缺血性心脏病是院内死亡率的主要原因。斯里兰卡急性冠脉综合征审计项目(ACSSLAP)是第一个评估国有医院的临床审计项目,其评估了患者特征、临床结果和国家提供的护理。近期,一项发表在杂志HEART上的ACSSLAP前瞻性地评估了所有管理ACS患者的国有医院提供的急诊护理、院内护理和出院计划。数据收集来自每个医院在2-4周时间内的连续30名患者。审计标准使用当地和国际建议。此项研究结果显示:

斯里兰卡的缺血性心脏病是院内死亡率的主要原因。斯里兰卡急性冠脉综合征审计项目(ACSSLAP)是第一个评估国有医院的临床审计项目,其评估了患者特征、临床结果和国家提供的护理。

近期,一项发表在杂志HEART上的ACSSLAP前瞻性地评估了所有管理ACS患者的国有医院提供的急诊护理、院内护理和出院计划。数据收集来自每个医院在2-4周时间内的连续30名患者。审计标准使用当地和国际建议。

此项研究结果显示:来自98家中的87家(88.7%)医院的数据招募了2177名患者,其中2116人确认患有ACS。平均年龄为61.4±11.8岁(范围20-95岁),男性为58.7%(n = 1242例)。不稳定型心绞痛患者813例(38.4%),非ST段抬高心肌梗死(NSTEMI)695例(32.8%),ST段抬高型心肌梗死(STEMI)608例(28.7%)。 STEMI(69.9%)和NSTEMI(61.4%)在男性中更多(P <0.001)。阿司匹林、氯吡格雷和他汀类药物在急性期和出院时给予超过90%的患者。在STEMI中,407例患者(66.9%)被再灌注; 384例患者(63.2%)接受纤维蛋白溶解治疗,仅23例患者(3.8%)接受了经皮冠状动脉介入治疗(PCI)。在<30分钟时间内仅有42.3%患者进行了溶栓,在<90分钟内有62.5%的患者进行了PCI。在出院时,β受体阻滞剂和ACE抑制剂/血管紧张素II受体阻滞剂分别仅给予50.7%和69.2%的患者,并且只有17.6%的患者进行了冠状动脉介入治疗。

此项研究结果表明:在ACS患者中,阿司匹林、氯吡格雷和他汀类药物的使用符合急性背景和出院时的审核标准。由于资源有限,绝大多数STEMI患者接受了纤维蛋白溶解比,而不是PCI。斯里兰卡的初级PCI,有计划的冠脉介入和及时溶栓治疗需要改善。

原始出处:
Galappatthy P, Bataduwaarachchi VR, et al. Management, characteristics and outcomes of patients with acute coronary syndrome in Sri Lanka. Heart. 2018 Feb 16. pii: heartjnl-2017-312404. doi: 10.1136/heartjnl-2017-312404.

本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=298355, encodeId=844e29835589, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Mar 21 18:08:57 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290066, encodeId=6447290066fe, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Feb 23 00:45:35 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356704, encodeId=963f1356e04a0, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Feb 22 03:08:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431129, encodeId=f2581431129fe, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Feb 22 03:08:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562849, encodeId=675a15628497d, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Feb 22 03:08:00 CST 2018, time=2018-02-22, status=1, ipAttribution=)]
    2018-03-21 wxl882001

    学习一下

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=298355, encodeId=844e29835589, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Mar 21 18:08:57 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290066, encodeId=6447290066fe, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Feb 23 00:45:35 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356704, encodeId=963f1356e04a0, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Feb 22 03:08:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431129, encodeId=f2581431129fe, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Feb 22 03:08:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562849, encodeId=675a15628497d, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Feb 22 03:08:00 CST 2018, time=2018-02-22, status=1, ipAttribution=)]
    2018-02-23 1209e435m98(暂无昵称)

    学习了.谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=298355, encodeId=844e29835589, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Mar 21 18:08:57 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290066, encodeId=6447290066fe, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Feb 23 00:45:35 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356704, encodeId=963f1356e04a0, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Feb 22 03:08:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431129, encodeId=f2581431129fe, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Feb 22 03:08:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562849, encodeId=675a15628497d, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Feb 22 03:08:00 CST 2018, time=2018-02-22, status=1, ipAttribution=)]
    2018-02-22 zhaojie88
  4. [GetPortalCommentsPageByObjectIdResponse(id=298355, encodeId=844e29835589, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Mar 21 18:08:57 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290066, encodeId=6447290066fe, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Feb 23 00:45:35 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356704, encodeId=963f1356e04a0, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Feb 22 03:08:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431129, encodeId=f2581431129fe, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Feb 22 03:08:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562849, encodeId=675a15628497d, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Feb 22 03:08:00 CST 2018, time=2018-02-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=298355, encodeId=844e29835589, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Mar 21 18:08:57 CST 2018, time=2018-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290066, encodeId=6447290066fe, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Feb 23 00:45:35 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356704, encodeId=963f1356e04a0, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Feb 22 03:08:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431129, encodeId=f2581431129fe, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Feb 22 03:08:00 CST 2018, time=2018-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562849, encodeId=675a15628497d, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Feb 22 03:08:00 CST 2018, time=2018-02-22, status=1, ipAttribution=)]
    2018-02-22 slcumt

相关资讯

Circulation:炎症学说开创者Peter Libby提出精准诊疗急性冠脉综合征:根据炎症和影像学可分四种类型

动脉粥样硬化炎症学说的开创者Peter Libby最近在Circualtion杂志发表了一篇重要文章。

Intern Med J:急性冠脉综合征的抗血小板治疗:氯吡格雷vs替格瑞洛

2017年11月,发表在《Intern Med J》的一项由新西兰科学家进行的研究考察了急性冠脉综合征的抗血小板治疗:氯吡格雷和替格瑞洛的结局和停药之间的差异。

AHA2017:GEMINI-ACS-1研究:药物基因检测对P2Y12抑制剂方案转换影响甚微

杜克大学医学中心Roe MT教授报道了GEMINI-ACS-1研究的一项新分析,评估了临床常规进行CYP2C19基因检测对急性冠脉综合征(ACS)患者P2Y12抑制剂方案转换的影响。

Lancet:多学科讨论:急性冠脉综合征患者PCI后降阶梯治疗不输标准治疗

2017年10月,发表在《Lancet》的一项由德国、匈牙利、波兰和奥地利科学家进行的随机、开放式标签的多中心试验(TROPICAL-ACS),考察了相比于标准普拉格雷治疗,指导降阶梯抗血小板治疗对经皮冠状动脉介入(PCI)治疗的急性冠状动脉综合征(ACS)患者的有效性和安全性。

Circulation:ACS后疾病稳定的患者:将依折麦布添加到辛伐他汀有“惊喜”

急性冠脉综合征(ACS)患者动脉粥样硬化血栓形成事件的风险增加。这些事件不局限于冠脉血管,也包括缺血性卒中——因长期失能风险而最令人恐惧的心血管事件。2017年12月,发表在《Circulation》的IMPROVE-IT(结局降低的改善:Vytorin有效性国际试验)试验,考察了依折麦布+他汀中预防ACS患者卒中的疗效。

HEART:两种PCI方法的比较!

近期,一项发表在杂志HEART上的研究旨在评估单次多支血管经皮冠状动脉介入治疗(PCI)的方法相对于分期多支血管的治疗对稳定性冠心病(CAD)或非ST段抬高急性冠脉综合征患者临床预后的影响。此项研究在京都PCI /冠状动脉旁路移植注册研究队列-2的冠状动脉再血管化结局研究中进行,共有2018名患者接受了选择性多支血管PCI治疗。主要终点指标为5年随访期间全因死亡、心肌梗死和卒中情况。最终,共有70